TSX:CRONPharmaceuticals
Cronos Group (TSX:CRON) Is Up 21.8% After U.S. Rescheduling Buzz And Dutch Deal News
In recent days, Cronos Group has been swept up in reports that the Trump administration may reclassify marijuana from Schedule I to Schedule III in the U.S., a move that would ease federal restrictions and taxation for the cannabis industry.
At the same time, Cronos agreed to acquire CanAdelaar B.V., the largest player in the Netherlands’ adult-use cannabis pilot program, signalling a push to build a meaningful European footprint alongside any regulatory shifts in its key North American...